open access

Vol 26, No 5 (2019)
Original articles — Clinical cardiology
Published online: 2018-03-26
Get Citation

Percutaneous renal artery denervation in patients with chronic systolic heart failure: A randomized controlled trial

Jun-Qing Gao, Wei Yang, Zong-Jun Liu
DOI: 10.5603/CJ.a2018.0028
·
Pubmed: 29611171
·
Cardiol J 2019;26(5):503-510.

open access

Vol 26, No 5 (2019)
Original articles — Clinical cardiology
Published online: 2018-03-26

Abstract

Background: Renal denervation (RDN) is as an effective treatment for heart failure (HF), but its effects on cardiac function of patients with HF are not well documented. Here, the aim was to investigate RDN’s effect on patients with chronic systolic HF, by conducting a single-center, prospective, randomized, and controlled study.


Methods: Sixty patients with chronic systolic HF were randomly assigned to the RDN or control groups, receiving percutaneous catheter-based RDN with radiofrequency ablation and drug treatment, respectively. All patients performed a 6-minute walk test, echocardiography, blood pressure measurement, and biochemical test, at both baseline and in a 6-month follow up.


Results: Over 6-month follow up, patients in RDN group showed a decrease in N-terminal pro-B-type natriuretic peptide (440.1 ± 226.5 pg/mL vs. 790.8 ± 287.0 pg/mL, p < 0.001, Cohen’s d = 1.14), an increase in left ventricular ejection fraction (39.1 ± 7.3% vs. 35.6 ± 3.3%, p = 0.017, Cohen’s d = 0.61), improved New York Heart Association class assessment (p = 0.01, Cohen’s d = 0.66), and decreased blood pressures (p < 0.001, Cohen’s d = 0.91), without reporting hypotension and syncope amaurosis. No significant between-group difference was observed for glomerular filtration rate and heart rate.


Conclusions: Renal denervation which effectively and safely improves patient’s cardiac function as well as exercise tolerance, could be considered as an effective treatment for chronic systolic HF.

Abstract

Background: Renal denervation (RDN) is as an effective treatment for heart failure (HF), but its effects on cardiac function of patients with HF are not well documented. Here, the aim was to investigate RDN’s effect on patients with chronic systolic HF, by conducting a single-center, prospective, randomized, and controlled study.


Methods: Sixty patients with chronic systolic HF were randomly assigned to the RDN or control groups, receiving percutaneous catheter-based RDN with radiofrequency ablation and drug treatment, respectively. All patients performed a 6-minute walk test, echocardiography, blood pressure measurement, and biochemical test, at both baseline and in a 6-month follow up.


Results: Over 6-month follow up, patients in RDN group showed a decrease in N-terminal pro-B-type natriuretic peptide (440.1 ± 226.5 pg/mL vs. 790.8 ± 287.0 pg/mL, p < 0.001, Cohen’s d = 1.14), an increase in left ventricular ejection fraction (39.1 ± 7.3% vs. 35.6 ± 3.3%, p = 0.017, Cohen’s d = 0.61), improved New York Heart Association class assessment (p = 0.01, Cohen’s d = 0.66), and decreased blood pressures (p < 0.001, Cohen’s d = 0.91), without reporting hypotension and syncope amaurosis. No significant between-group difference was observed for glomerular filtration rate and heart rate.


Conclusions: Renal denervation which effectively and safely improves patient’s cardiac function as well as exercise tolerance, could be considered as an effective treatment for chronic systolic HF.

Get Citation

Keywords

renal denervation; sympathetic nervous system; heart failure; blood pressure; cardiology

About this article
Title

Percutaneous renal artery denervation in patients with chronic systolic heart failure: A randomized controlled trial

Journal

Cardiology Journal

Issue

Vol 26, No 5 (2019)

Pages

503-510

Published online

2018-03-26

DOI

10.5603/CJ.a2018.0028

Pubmed

29611171

Bibliographic record

Cardiol J 2019;26(5):503-510.

Keywords

renal denervation
sympathetic nervous system
heart failure
blood pressure
cardiology

Authors

Jun-Qing Gao
Wei Yang
Zong-Jun Liu

References (19)
  1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119(3): e21–181.
  2. Dhakal P, Liu K, Kozman H, et al. Renal Denervation in Heart Failure: A New Therapeutic Paradigm. Clin Med Insights Cardiol. 2015; 9(Suppl 1): 101–104.
  3. Böhm M, Ewen S, Kindermann I, et al. Renal denervation and heart failure. Eur J Heart Fail. 2014; 16(6): 608–613.
  4. Schlaich MP, Socratous F, Hennebry S, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009; 20(5): 933–939.
  5. Patel HC, Dhillon PS, Mahfoud F, et al. The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol. 2014; 103(5): 337–344.
  6. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376(9756): 1903–1909.
  7. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373(9671): 1275–1281.
  8. Bhatt DL, Kandzari DE, O'Neill WW, et al. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370(15): 1393–1401.
  9. Abramovitch J, Arviddson B, Dunn K, et al. The radiation tolerance of specific optical fibers for the LHC upgrades. Physics Procedia. 2012; 37: 1630–1643.
  10. Liu Q, Li Z, Zhang Qi, et al. [Effects of renal denervation on left atrial fibrosis in rats with isoproterenol induced chronic heart failure]. Zhonghua Xin Xue Guan Bing Za Zhi. 2015; 43(12): 1040–1045.
  11. Xie Y, Liu Q, Xu Y, et al. [Effect of catheter-based renal sympathetic denervation in pigs with rapid pacing induced heart failure]. Zhonghua Xin Xue Guan Bing Za Zhi. 2014; 42(1): 48–52.
  12. Davies JE, Manisty CH, Petraco R, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013; 162(3): 189–192.
  13. Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986; 73(4): 615–621.
  14. Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014; 114(11): 1815–1826.
  15. Kshatriya S, Kozman H, Siddiqui D, et al. The kidney in heart failure: friend or foe? Am J Med Sci. 2012; 344(3): 228–232.
  16. Tan LH, Li XG, Guo YZ, et al. [Effect of renal sympathetic denervation on left ventricular hypertrophy and inflammatory factors in spontaneously hypertensive rats]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013; 42(5): 550–555.
  17. Mahfoud F, Urban D, Teller D, et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J. 2014; 35(33): 2224–2231.
  18. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012; 59(10): 901–909.
  19. Patel HC, Rosen SD, Hayward C, et al. Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. Eur J Heart Fail. 2016; 18(6): 703–712.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl